<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03064087</url>
  </required_header>
  <id_info>
    <org_study_id>WIV-ISP_2017_001</org_study_id>
    <nct_id>NCT03064087</nct_id>
  </id_info>
  <brief_title>Validation of Human Papillomavirus Assays and Collection Devices for Self-samples and Urine Samples</brief_title>
  <acronym>VALHUDES</acronym>
  <official_title>Validation of Human Papillomavirus Assays and Collection Devices for HPV Testing on Self-samples and First-void Urine Samples (VALHUDES)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marc Arbyn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Algemeen Medisch Laboratorium (Antwerpen)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regionaal Ziekenhuis Heilig Hart Tienen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Belgian Scientific Institute of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The VALHUDES study is a Diagnostic Test Accuracy study that aims to document the clinical
      accuracy of hrHPV testing on urine samples, collected under standardised and optimised
      conditions, and on two types of vaginal self-samples and compare results with those from
      matching samples taken by a clinician.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The samples are collected from patients referred to colposcopy because of prior cervical
      abnormalities. The patient takes at home two urine samples with the Colli-Pee device (a
      device that allows to collect first-void urine), the day before the visit to the colposcopy
      centre. At the colposcopy centre, two vaginal self-samples are taken by the patient herself:
      one with a cotton swab and a second with a plastic brush. Finally, the gynecologist takes a
      cervical Pap smear with a Cervex-Brush Combi.

      A real-time PCR test will be used to detect DNA of high-risk HPV types. It is possible that
      in the future also other tests will be validated on these samples. The colposcopy and
      histological findings will be used as the gold standard. The main purpose of the study is to
      assess the relative diagnostic tests accuracy of hrHPV testing on self- and urine samples
      compared to hrHPV testing on cervical samples taken by a clinician. Furthermore, the
      participating women will receive also a questionnaire which can give insights into the
      attitudes and preferences of the women with regard to the self-sampling devices.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical accuracy</measure>
    <time_frame>up to 18 months</time_frame>
    <description>• Relative sensitivity and specificity of hrHPV testing on first-void urine vs clinician-collected samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical accuracy</measure>
    <time_frame>up to 18 months</time_frame>
    <description>• Relative sensitivity and specificity of hrHPV testing on vaginal self-samples vs clinician-collected samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical accuracy</measure>
    <time_frame>up to 18 months</time_frame>
    <description>• Absolute sensitivity and specificity for finding underlying CIN2+ of hrHPV testing on urine, self- and clinician-collected samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical accuracy</measure>
    <time_frame>up to 18 months</time_frame>
    <description>• Relative sensitivity and specificity of hrHPV testing on samples taken with the Qvintip vs the Evalyn Brush (non-matched comparison) and on urine samples vs the different vaginal self-samples (matched comparison)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical accuracy</measure>
    <time_frame>up to 18 months</time_frame>
    <description>• An intermediate statistical analysis will be performed after that 100 patients are included to verify whether all processes run as expected. Possible protocol adjustments may be considered after this intermediate analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analytical performance</measure>
    <time_frame>up to 18 months</time_frame>
    <description>• Concordance of the presence of hrHPV and of the partial HPV genotyping results applied on urine, self- and clinician-collected samples; correlation in viral load (expressed as cycle number values) between samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analytical performance</measure>
    <time_frame>up to 18 months</time_frame>
    <description>• Positivity rates for beta-globin in the different types of samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analytical performance</measure>
    <time_frame>up to 18 months</time_frame>
    <description>• Correlation of cycle number values for HPV16, HPV18, other hrHPV and beta-globin between the different types of samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptance and preferences</measure>
    <time_frame>up to 18 months</time_frame>
    <description>• Acceptance of self-sampling, preferences of women (assessed from a questionnaire and from participation rate [number of women who participate/number of women approached]).</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cervical Intraepithelial Neoplasia Grade 2/3</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Colli-Pee</intervention_name>
    <description>First, two first-void urine samples will be collected with the Colli-Pee device (Novosanis NV, Wijnegem, Belgium) at home, the day before a visit to the colposcopy centre at a gynecology clinic.</description>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Multi-Collect Swab</intervention_name>
    <description>At the colposcopy clinic, one vaginal self-sample will be collected with the Multi-Collect Swab (Abbott GmbH &amp; Co. KG, Wiesbaden, Germany).</description>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evalyn Brush</intervention_name>
    <description>Another vaginal self-sample will be collected also at the colposcopy centre either with the Evalyn Brush (Rovers Medical Devices B.V., Oss, Netherlands)</description>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Qvintip</intervention_name>
    <description>or with Qvintip (Aprovix AB, Uppsala, Sweden).</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Abbott RealTime High Risk HPV</intervention_name>
    <description>The hrHPV assay used, will be the Abbott PCR (Abbott GmbH &amp; Co. KG, Wiesbaden, Germany), which detects separately DNA of HPV16 and HPV18, as well as the pool of twelve other hrHPV types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). The accuracy of this PCR assay for the detection of CIN2+ will be determined on all samples: on the mixed two urine samples and on the vaginal and cervical samples. Furthermore, it is possible that in the future other assays will be validated.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      First-void urine sample, vaginal self-sample and cervical cell sample collected by a
      gynecologist. No human DNA is extracted from the samples but the samples can contain HPV DNA.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        500 women referred to a participating Belgian colposcopy centre (University Hospital of
        Ghent, Brussels and Antwerp, Hospital of Tienen) because of a previous abnormal cervical
        cancer screening test result, will be enrolled after obtaining informed consent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with previous abnormal cervical cancer screening test results

          -  Women between the ages of 25 and 64

        Exclusion Criteria:

          -  Hysterectomised women

          -  Women with known pregnancy

          -  Non-consenting women

          -  Women that are not able to understand and to sign the informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Marc Arbyn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unit of Cancer Epidemiology, Belgian Cancer Centre, Scientific Institute of Public Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Arbyn</last_name>
    <phone>+3226425021</phone>
    <email>marc.arbyn@wiv-isp.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Brussels</name>
      <address>
        <city>Brussels</city>
        <state>Brussels Capital Region</state>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe De Sutter</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Ghent</name>
      <address>
        <city>Ghent</city>
        <state>East Flanders</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Weyers</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heilig Hart Ziekenhuis Tienen</name>
      <address>
        <city>Tienen</city>
        <state>Flemish Brabant</state>
        <zip>3300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert Donders</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Antwerp</name>
      <address>
        <city>Antwerp</city>
        <zip>2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wiebren Tjalma</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, Minozzi S, Bellisario C, Banzi R, Zhao FH, Hillemanns P, Anttila A. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014 Feb;15(2):172-83. doi: 10.1016/S1470-2045(13)70570-9. Epub 2014 Jan 14. Review.</citation>
    <PMID>24433684</PMID>
  </reference>
  <reference>
    <citation>Arbyn M, Snijders PJ, Meijer CJ, Berkhof J, Cuschieri K, Kocjan BJ, Poljak M. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect. 2015 Sep;21(9):817-26. doi: 10.1016/j.cmi.2015.04.015. Epub 2015 May 1. Review.</citation>
    <PMID>25936581</PMID>
  </reference>
  <reference>
    <citation>Arbyn M, Castle PE. Offering Self-Sampling Kits for HPV Testing to Reach Women Who Do Not Attend in the Regular Cervical Cancer Screening Program. Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):769-72. doi: 10.1158/1055-9965.EPI-14-1417. Epub 2015 Feb 24.</citation>
    <PMID>25713024</PMID>
  </reference>
  <reference>
    <citation>Verdoodt F, Jentschke M, Hillemanns P, Racey CS, Snijders PJ, Arbyn M. Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials. Eur J Cancer. 2015 Nov;51(16):2375-85. doi: 10.1016/j.ejca.2015.07.006. Epub 2015 Aug 18. Review.</citation>
    <PMID>26296294</PMID>
  </reference>
  <reference>
    <citation>Vorsters A, Van den Bergh J, Micalessi I, Biesmans S, Bogers J, Hens A, De Coster I, Ieven M, Van Damme P. Optimization of HPV DNA detection in urine by improving collection, storage, and extraction. Eur J Clin Microbiol Infect Dis. 2014 Nov;33(11):2005-14. doi: 10.1007/s10096-014-2147-2. Epub 2014 Jun 12.</citation>
    <PMID>24916950</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2017</study_first_submitted>
  <study_first_submitted_qc>February 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Belgian Scientific Institute of Public Health</investigator_affiliation>
    <investigator_full_name>Marc Arbyn</investigator_full_name>
    <investigator_title>Coordinator Unit Cancer Epidemiology (Belgian Cancer Centre)</investigator_title>
  </responsible_party>
  <keyword>Self-Sampling</keyword>
  <keyword>HPV Testing</keyword>
  <keyword>Diagnostic Test Accuracy</keyword>
  <keyword>Cervical Intraepithelial Neoplasia</keyword>
  <keyword>Urine</keyword>
  <keyword>Cervical Cancer Screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

